Latest On ENDRA Life Sciences Inc (NDRA):
About ENDRA Life Sciences Inc (NDRA):
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
General
- Name ENDRA Life Sciences Inc
- Symbol NDRA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 15
- Fiscal Year EndDecember
- IPO Date2017-05-09
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Gic SubIndustryHealth Care Equipment
- Web URLhttp://www.endrainc.com
Valuation
- Price/Book (Most Recent Quarter) 26.03
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.18
- Return on Assets -172%
- Return on Equity -603%
- Earnings Per Share -$1.63
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 109.11 million
- EBITDA -9065316
- Analyst Target Price $4.75
- Book Value Per Share $0.13
Share Statistics
- Shares Outstanding 37.59 million
- Shares Float 22.67 million
- % Held by Insiders 548%
- % Held by Institutions 2.79%
- Shares Short 446816
- Shares Short Prior Month 373732
- Short Ratio 0.16
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 1.3
- 52 Week High $3.09
- 52 Week Low $0.6
- 50 Day Moving Average 2.35
- 200 Day Moving Average 1.25
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ENDRA Life Sciences Inc (NDRA) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
ENDRA Life Sciences Inc (NDRA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-11-16 | $N/A | -$0.15 | -$0.17 | 13.44% |
2020-06-30 | 2020-08-14 | $N/A | -$0.20 | -$0.27 | 25.93% |
2020-03-31 | 2020-05-14 | $N/A | -$0.29 | -$0.34 | 13.43% |
2019-12-31 | 2020-03-26 | $N/A | -$1.20 | -$0.29 | -321.05% |
2019-09-30 | 2019-11-13 | $N/A | -$0.46 | -$0.34 | -35.29% |
2019-06-30 | 2019-08-08 | $N/A | -$0.31 | -$0.31 | 0% |
2019-03-31 | 2019-05-14 | $N/A | -$0.37 | -$0.30 | -23.33% |
2018-12-31 | 2019-03-11 | $N/A | -$0.32 | ||
2018-09-30 | 2018-09-30 | $N/A | -$0.70 | ||
2018-06-30 | 2018-06-30 | $-6174 | -$0.47 | ||
2018-03-31 | 2018-03-31 | $6174 | -$0.72 | ||
2017-12-31 | 2017-12-31 | $7000 | -$0.58 | ||
2017-09-30 | 2017-09-30 | $287000 | -$0.23 | ||
2017-06-30 | 2017-06-30 | $58000 | -$0.59 |
ENDRA Life Sciences Inc (NDRA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Research Development | N/A | N/A | 1.52 million | 2.03 million | 1.47 million |
Income Before Tax | N/A | N/A | -3.32 million | -4.81 million | -3.41 million |
Selling General Administrative | N/A | N/A | 1.58 million | 1.1 million | 1.17 million |
Gross Profit | N/A | N/A | N/A | N/A | N/A |
Ebit | N/A | N/A | -3.06 million | -3.13 million | -2.64 million |
Operating Income | N/A | N/A | -3.1 million | -3.13 million | -2.64 million |
Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
Total Revenue | N/A | N/A | N/A | N/A | N/A |
Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
Total Other Income Expense Net | N/A | N/A | 6617 | -1.68 million | -773029 |
Net Income From Continuing Operations | N/A | N/A | -3.32 million | -4.81 million | -3.41 million |
Net Income Applicable to Common Shares | -3.65 million | -2.89 million | N/A | -9.03 million | -3.41 million |
Cash Flow:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Investments | N/A | N/A | -22350 | N/A | N/A |
Change to Liabilities | 49509 | -234798 | N/A | 530503 | -162169 |
Total Cash Flow from Investing Activities | 11867 | N/A | N/A | -38357 | N/A |
Net Borrowings | N/A | 337084 | N/A | N/A | 2.49 million |
Total Cash Flow from Financial Activities | N/A | N/A | 39238 | 5.84 million | 2.49 million |
Change to Operating Activities | 507754 | -705853 | N/A | 45994 | 37124 |
Change in Cash | N/A | N/A | -3.07 million | 3.9 million | 7771 |
Total Cash from Operating Activities | -2.13 million | -3.45 million | -3.09 million | -1.91 million | -2.48 million |
Depreciation | N/A | N/A | 37501 | 55338 | 19929 |
Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
Change to Inventory | N/A | N/A | -61493 | 14389 | -53550 |
Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
Other Cash Flow from Financing Activities | 42260 | N/A | N/A | N/A | N/A |
Change to Net Income | 532112 | 506040 | N/A | 628503 | 361083 |
Capital Expenditures | N/A | N/A | 22350 | 38357 | N/A |
Balance Sheet:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | N/A | 1.88 million | 2.42 million | 2.21 million |
Total Stockholder Equity | N/A | N/A | 2.52 million | 4.76 million | 1.4 million |
Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
Total Assets | N/A | N/A | 4.4 million | 7.18 million | 3.62 million |
Common Stock | 2500 | 1644 | N/A | 842 | 751 |
Other Current Assets | 101451 | N/A | 121951 | 130701 | 366390 |
Retained Earnings | -55.09 million | -51.43 million | -48.54 million | -45.22 million | -36.19 million |
Other Liabilities | N/A | N/A | N/A | N/A | N/A |
Other Assets | N/A | N/A | N/A | N/A | N/A |
Cash | N/A | N/A | 3.1 million | 6.17 million | 2.28 million |
Total Current Liabilities | 1.4 million | N/A | 1.55 million | 2.07 million | 1.85 million |
Other Stockholder Equity | 138538 | 181438 | N/A | 43528 | N/A |
Property, Plant & Equipment | 581680 | 587307 | N/A | 641170 | 639286 |
Total Current Assets | 4.78 million | N/A | 3.77 million | 6.54 million | 2.98 million |
Long Term Investments | N/A | N/A | N/A | N/A | N/A |
Net Tangible Assets | 3.33 million | 976880 | N/A | 4.76 million | 1.4 million |
Short Term Investments | N/A | N/A | N/A | N/A | N/A |
Long Term Debt | N/A | N/A | N/A | N/A | N/A |
Inventory | 323208 | N/A | 174935 | 113442 | 127831 |
Accounts Payable | 1.33 million | N/A | 1.24 million | 1.71 million | 1.2 million |
ENDRA Life Sciences Inc (NDRA) Chart:
ENDRA Life Sciences Inc (NDRA) News:
Below you will find a list of latest news for ENDRA Life Sciences Inc (NDRA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ENDRA Life Sciences Inc (NDRA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Latest NDRA Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 6:18 PM EST | 100 | $0.26 |
Jun 13, 2022 6:20 PM EST | 200 | $0.2562 |
Jun 13, 2022 6:20 PM EST | 100 | $0.2569 |
Jun 13, 2022 6:21 PM EST | 100 | $0.255 |
Jun 13, 2022 6:33 PM EST | 100 | $0.2578 |
ENDRA Life Sciences Inc (NDRA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/0001209191-20-038682-index.htm |
2020-01-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1681682/000000000020000371/0000000000-20-000371-index.htm |
2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120005185/0001209191-20-005185-index.htm |
2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120005187/0001209191-20-005187-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024209/0001209191-20-024209-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024211/0001209191-20-024211-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024213/0001209191-20-024213-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024214/0001209191-20-024214-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024215/0001209191-20-024215-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024216/0001209191-20-024216-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024217/0001209191-20-024217-index.htm |
2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024218/0001209191-20-024218-index.htm |
2020-04-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024483/0001209191-20-024483-index.htm |
2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024484/0001209191-20-024484-index.htm |
2020-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120031547/0001209191-20-031547-index.htm |
2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120031895/0001209191-20-031895-index.htm |
2020-05-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032219/0001209191-20-032219-index.htm |
2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032502/0001209191-20-032502-index.htm |
2020-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032826/0001209191-20-032826-index.htm |
2020-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032827/0001209191-20-032827-index.htm |
2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120033102/0001209191-20-033102-index.htm |
2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035185/0001209191-20-035185-index.htm |
2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035436/0001209191-20-035436-index.htm |
2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035437/0001209191-20-035437-index.htm |
2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035438/0001209191-20-035438-index.htm |
2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/0001209191-20-035439-index.htm |
2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120038680/0001209191-20-038680-index.htm |
2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120038681/0001209191-20-038681-index.htm |
2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/0001209191-20-038682-index.htm |
2020-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120042615/0001209191-20-042615-index.htm |
2020-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120043430/0001209191-20-043430-index.htm |
2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120053429/0001209191-20-053429-index.htm |
2020-10-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1681682/000120919120055831/0001209191-20-055831-index.htm |
2020-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420000453/0001654954-20-000453-index.htm |
2020-01-22 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1681682/000165495420000665/0001654954-20-000665-index.htm |
2020-01-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1681682/000165495420000666/0001654954-20-000666-index.htm |
2020-01-28 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420000845/0001654954-20-000845-index.htm |
2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420002407/0001654954-20-002407-index.htm |
2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003330/0001654954-20-003330-index.htm |
2020-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003346/0001654954-20-003346-index.htm |
2020-03-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003349/0001654954-20-003349-index.htm |
2020-03-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003391/0001654954-20-003391-index.htm |
2020-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003393/0001654954-20-003393-index.htm |
2020-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003787/0001654954-20-003787-index.htm |
2020-04-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420003997/0001654954-20-003997-index.htm |
2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1681682/000165495420004207/0001654954-20-004207-index.htm |
2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420004473/0001654954-20-004473-index.htm |
2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1681682/000165495420004632/0001654954-20-004632-index.htm |
2020-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1681682/000165495420004633/0001654954-20-004633-index.htm |
2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420005473/0001654954-20-005473-index.htm |
2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420005509/0001654954-20-005509-index.htm |
2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420006146/0001654954-20-006146-index.htm |
2020-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420006789/0001654954-20-006789-index.htm |
2020-07-22 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1681682/000165495420007923/0001654954-20-007923-index.htm |
2020-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420007924/0001654954-20-007924-index.htm |
2020-08-03 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1681682/000165495420008321/0001654954-20-008321-index.htm |
2020-08-10 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1681682/000165495420008698/0001654954-20-008698-index.htm |
2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420009164/0001654954-20-009164-index.htm |
2020-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420009242/0001654954-20-009242-index.htm |
2020-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420009423/0001654954-20-009423-index.htm |
2020-09-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420009764/0001654954-20-009764-index.htm |
2020-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420010426/0001654954-20-010426-index.htm |
2020-09-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1681682/000165495420010480/0001654954-20-010480-index.htm |
2020-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1681682/000165495420010481/0001654954-20-010481-index.htm |
2020-01-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1681682/999999999520000169/9999999995-20-000169-index.htm |
ENDRA Life Sciences Inc (NDRA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ENDRA Life Sciences Inc (NDRA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 548%Institutional Ownership: 279%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2020-04-09 | Francois Roger Michelon | Chief Executive Officer | Buy | 123,064.00 | 155,561.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024209/0001209191-20-024209-index.htm | ||
2020-04-09 | Michael Milos Thornton | Chief Technology Officer | Buy | 96,213.00 | 215,963.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024211/0001209191-20-024211-index.htm | ||
2020-04-09 | ANTHONY DIGIANDOMENICO | Director | Buy | 42,857.00 | 242,083.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024215/0001209191-20-024215-index.htm | ||
2020-05-22 | ANTHONY DIGIANDOMENICO | Director | Buy | 10,000.00 | 0.78 | 7,800.00 | 252,083.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120031895/0001209191-20-031895-index.htm |
2020-05-28 | ANTHONY DIGIANDOMENICO | Director | Buy | 5,000.00 | 0.90 | 4,500.00 | 276,509.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032827/0001209191-20-032827-index.htm |
2020-06-08 | ANTHONY DIGIANDOMENICO | Director | Buy | 5,000.00 | 0.92 | 4,600.00 | 281,509.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120035185/0001209191-20-035185-index.htm |
2020-04-09 | Lou Basenese | Director | Buy | 41,587.00 | 41,587.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024484/0001209191-20-024484-index.htm | ||
2020-04-09 | Alexander Y Tokman | Director | Buy | 42,857.00 | 42,857.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024217/0001209191-20-024217-index.htm | ||
2020-04-09 | Sanjiv Sam Gambhir | Director | Buy | 42,857.00 | 42,857.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024218/0001209191-20-024218-index.htm | ||
2020-04-09 | Michael Harsh | Director | Buy | 42,857.00 | 52,857.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024216/0001209191-20-024216-index.htm | ||
2020-05-21 | Lou Basenese | Director | Buy | 10,000.00 | 0.71 | 7,100.00 | 59,068.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120031547/0001209191-20-031547-index.htm |
2020-05-26 | Lou Basenese | Director | Buy | 10,000.00 | 0.82 | 8,200.00 | 69,068.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032219/0001209191-20-032219-index.htm |
2020-10-01 | Renaud Bertrand Maloberti | Chief Commercial Officer | Sell | 10,000.00 | 0.72 | 7,200.00 | 76,580.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120053429/0001209191-20-053429-index.htm |
2020-05-27 | Lou Basenese | Director | Buy | 10,000.00 | 0.85 | 8,500.00 | 79,068.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032502/0001209191-20-032502-index.htm |
2020-04-09 | Renaud Bertrand Maloberti | Chief Commercial Officer | Buy | 86,580.00 | 86,580.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024214/0001209191-20-024214-index.htm | ||
2020-05-28 | Lou Basenese | Director | Buy | 10,000.00 | 0.91 | 9,100.00 | 89,068.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120032826/0001209191-20-032826-index.htm |
2020-05-29 | Lou Basenese | Director | Buy | 10,000.00 | 0.90 | 9,000.00 | 99,068.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120033102/0001209191-20-033102-index.htm |
2020-04-09 | David R. Wells | Chief Financial Officer | Buy | 79,653.00 | 99,653.00 | https://www.sec.gov/Archives/edgar/data/1681682/000120919120024213/0001209191-20-024213-index.htm |